腦炎治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Encephalitis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年03月07日 | 出版商:

Global Market Insights Inc. | 英文 104 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球腦炎治療市場價值為 223 億美元，預計 2025-2034 年期間複合年成長率為 5.2%。由於病毒感染激增以及環境變化導致的致病媒介接觸增加，全球腦炎病例持續上升，該市場有望穩步擴張。隨著越來越多的人被診斷出患有這種嚴重的神經系統疾病，醫療保健系統面臨越來越大的壓力，需要提供及時有效的治療方案。媒介傳播疾病的盛行率不斷上升，加上老年人口的成長，更容易患腦炎，加速了對先進治療方案的需求。

此外，下一代抗病毒藥物、免疫療法和改進的診斷技術的引入正在進一步重塑腦炎治療的模式。醫療保健提供者和製藥公司正在共同努力創新治療途徑，不僅可以解決急性炎症，還可以防止長期神經損傷。尤其是在已開發經濟體中，人們越來越重視早期診斷和干涉，這為市場擴張創造了有利的環境。除此之外，公眾意識的提高和政府主導的健康舉措正在推動發展中國家對更好的治療可及性的需求，使腦炎治療成為全球醫療保健的重點領域。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	223億美元
預測值	365億美元
複合年成長率	5.2%

根據疾病類型，市場分為兩大類：原發性腦炎和繼發性腦炎。原發性腦炎是由病毒感染直接導致腦部發炎的疾病，2024 年該疾病佔全球市場的 69.8%。隨著病毒感染發生率的上升，特別是透過蚊子和蜱蟲傳播的病毒感染，原發性腦炎病例也在增加，對有效治療方案的需求龐大。抗病毒藥物對於治療這些病例至關重要，因為它們有助於減少發炎和減輕神經系統併發症。此外，氣候變遷持續影響媒介傳播疾病的傳播，直接影響原發性腦炎的流行，進而增加對治療介入的需求。

根據治療類型，腦炎治療市場包括抗生素、類固醇注射、免疫球蛋白療法、血漿置換、抗病毒藥物和其他療法。其中，抗病毒藥物在2024年創收63億美元，成為主導領域。對抗病毒藥物的強勁需求主要是由於全球病毒性腦炎病例數量的增加。這些藥物已被證明在控制發炎和預防嚴重腦損傷方面有效，並已成為標準治療方案的重要組成部分。預計，對新型抗病毒化合物的研發力度不斷加大，加上政府的支持措施和診斷工具的增強，將在未來十年加強該領域的成長軌跡。

2024 年，美國腦炎治療市場佔了 92.6% 的佔有率，創收 80 億美元，預計到 2034 年將達到 129 億美元。美國的成長得益於疾病意識的提高、診斷技術的快速進步以及創新療法的廣泛普及。該國強大的醫療保健基礎設施加上大量的醫療保健支出確保了患者能夠獲得尖端治療，鞏固了該國在腦炎治療領域的領先地位。

The Global Encephalitis Treatment Market was valued at USD 22.3 billion in 2024 and is projected to grow at a CAGR of 5.2% during 2025-2034. This market is poised for steady expansion as cases of encephalitis continue to rise worldwide, driven by a surge in viral infections and increasing exposure to disease-causing vectors due to environmental changes. As more individuals are diagnosed with this serious neurological condition, healthcare systems are under growing pressure to provide timely and effective treatment options. The rising prevalence of vector-borne diseases, combined with the growing elderly population more susceptible to encephalitis, is accelerating the demand for advanced therapeutic solutions.

Additionally, the introduction of next-generation antiviral agents, immunotherapies, and improved diagnostic technologies is further reshaping the landscape of encephalitis treatment. Healthcare providers and pharmaceutical companies are working together to innovate treatment pathways that not only address acute inflammation but also prevent long-term neurological damage. The growing emphasis on early diagnosis and intervention, especially in developed economies, is creating a favorable environment for market expansion. Alongside this, increased public awareness and government-led health initiatives are pushing the demand for better treatment accessibility across developing nations, making encephalitis treatment a key focus area in global healthcare.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$22.3 Billion
Forecast Value	$36.5 Billion
CAGR	5.2%

The market is segmented into two primary categories based on disease type: primary encephalitis and secondary encephalitis. Primary encephalitis, directly caused by viral infections leading to brain inflammation, dominated the global market in 2024 with a 69.8% share. As incidences of viral infections climb, especially those transmitted by mosquitoes and ticks, primary encephalitis cases are growing, creating significant demand for effective treatment solutions. The availability of antiviral drugs is essential in managing these cases, as they help reduce inflammation and mitigate neurological complications. Moreover, climate change continues to influence the spread of vector-borne diseases, directly impacting the prevalence of primary encephalitis and subsequently driving up the need for therapeutic interventions.

Based on treatment type, the encephalitis treatment market includes antibiotics, steroid injections, immunoglobulin therapy, plasmapheresis, antiviral agents, and other therapies. Among these, antiviral agents generated USD 6.3 billion in 2024, emerging as a dominant segment. The strong demand for antiviral medications is primarily fueled by the rising number of viral encephalitis cases worldwide. These drugs have become a critical part of standard treatment regimens due to their proven efficacy in managing inflammation and preventing serious brain damage. Increasing research and development efforts toward novel antiviral compounds, along with supportive government initiatives and enhanced diagnostic tools, are expected to strengthen this segment's growth trajectory over the next decade.

The United States Encephalitis Treatment Market accounted for a substantial 92.6% share in 2024, generating USD 8 billion, and is forecasted to reach USD 12.9 billion by 2034. Growth in the U.S. is driven by heightened disease awareness, rapid diagnostic advancements, and widespread availability of innovative treatments. The country's robust healthcare infrastructure, coupled with significant healthcare spending, ensures that patients have access to cutting-edge therapies, reinforcing the nation's position as a leader in the encephalitis treatment space.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of encephalitis
  - 3.2.1.2 Growing awareness about encephalitis treatment
  - 3.2.1.3 Increased investment in research and development by pharmaceutical companies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

5.1 Key trends
5.2 Primary encephalitis
5.3 Secondary encephalitis

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2034 ($ Mn)

6.1 Key trends
6.2 Antiviral agents
6.3 Steroid injections
6.4 Antibiotics
6.5 Immunoglobulin therapy
6.6 Plasmapheresis
6.7 Other treatments

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE